[das]

It looks like they evaluated 920 patients with invasive breast cancer presenting to a single center in Scotland between June 2000 and June 2003. This time period was before Herceptin therapy was licensed there.

It appears to be a descriptive study. They compared the characteristics (ER+/-, Grade, node status, etc) for HER2+ and HER2- patients. They also looked at the 5-year DFS and OS for HER2+ and HER2- patients stratified by the different characteristics: for example LN-HER2- had DFS of 91.6% and LN-HER2+ had DFS of 87.6%. They also present some survival curves for combinations of HER2 status and other characteristics as well as a regression model showing the effects of each characteristic 'adjusted for' the other characteristics.